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ABSTRACT 
Introduction: Esophagectomy is the main form of curative treatment for esophageal cancer 
and has a high morbidity rate. Neoadjuvant chemo- (CT) or chemoradiotherapy (CRT) is 
employed to increase long-term survival. To improve perioperative care the effects of 
measures taken to improve surgical exposure i.e. one-lung ventilation (OLV) and the effects 
of adding radio- to chemotherapy needs to be understood. 
Aims  
I. Compare inflammatory response and factors regulation pulmonary vascular tone 
after one- and two-lung ventilation during esophageal resection (paper I-II). 
II. Compare the effects of chemotherapy and chemoradiotherapy on cardiac function, 
perioperative hemodynamics and inflammatory response (paper III-V). 
Methods: Study one (papers I-II) was a randomised controlled trial comparing one- (n=16) 
vs. two-lung ventilation (n=14) during esophagectomy. Cytokines, complement activation 
markers, nitrite and endothelin were measured in plasma during and after surgery. Lung 
biopsies acquired before and after the thoracic part of the operation were accesses for levels 
of iNOS and vascular congestion. Study two (papers III-V) was a single centre cohort from 
within a multi-centre randomised controlled trial comparing CT vs. CRT regarding complete 
histological response. In paper III cardiac function following neoadjuvant treatment was 
evaluated in 40 patients as intention to treat (CT n=23, CRT n=17) using echocardiography 
with strain and tissue doppler analysis as well as plasma NT-proBNP. In paper IV the 
perioperative hemodynamic profile was investigated in 31 patients as per protocol (CT n=17, 
CRT n=14) using LiDCOplus. Measurements were performed before, during and after 
surgery. In addition plasma NT-proBNP and Troponin T were measured repeatedly. In paper 
V, concerning the same group of patients as in paper IV cytokines and complement activation 
markers in plasma were measured before, during and after surgery. In perioperative lung 
biopsies cytokine mRNA was measured and the number of CD45 positive cells counted. 
Results: In study one, inflammatory markers, factors regulating pulmonary vascular tone, 
iNOS levels and pulmonary congestion were similar between the groups apart from the 
terminal complement complex, C5b-9, which was increased in the OLV group on the 3rd and 
10th postoperative day. In study two, a decrease of septal systolic function and global 
diastolic function was seen in the CRT group as well as a lower preoperative cardiac index. 
However, when challenged by surgery a similar hemodynamic profile was seen in both 
groups. IL-β mRNA was higher in lung biopsies from patients that had received CRT, but 
there were no differences regarding systemic inflammation. Respiratory complications and 
other types of morbidity were similar in the CRT and CT groups.  
Conclusions: One-lung ventilation during esophagectomy increases activation of the 
complement system compared to two-lung ventilation but does not appear to induce factors 
related to pulmonary vascular tone. CRT induces a slight impairment of cardiac function 
compared to CT, an effect that did not persist when the cardiovascular system was challenged 
by surgery. Thus CRT as administered in this study appears safe from a cardiovascular 
perspective. However, CRT increases local inflammation in the lung, which might affect 
postoperative morbidity.  
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1 INTRODUCTION 
1.1.1 Etiology of esophageal cancer 
Already in the 1930s Craver and Watson reported excessive alcohol intake, smoking, low 
socioeconomic status, poor oral health and intake of hot drinks as risk factors for esophageal 
cancer
1
. Esophageal cancer is classified as into two subtypes based on histology, and their 
aetiologies differ. Esophageal squamous cell carcinoma (ESCC) has been and still is the 
dominant cancer type worldwide. However, since the 1970s there has been a steady increase 
in the incidence of esophageal adenocarcinoma (EA) in the distal third of the esophagus and 
in particular in the gastro-esophageal junction (GE-junction). High alcohol consumption, 
smoking, low socioeconomic status and low intake of fresh fruit and vegetables are still 
considered as risk factors for ESCC
2
. With the exception of smoking, these risk factors seem 
to be less important for the development of EA. Gastroesophageal reflux and obesity, which 
also may be  related to each other, have been identified as the predominant  risk factors for 
EA in the Western world
2
. The decreased incidence of Helicobacter pylori in the Western 
populations may be of importance for the pathogenesis although this theory is controversial
3
.  
1.1.2 Incidence and prevalence 
Esophageal cancer is the 8th most common cancer in the world and is, because of its poor 
prognosis, ranked 6th in mortality
4
. The incidence of ESCC is stable or even declining 
slightly whereas the incidence of EA is increasing rapidly in the western world, where EA is 
now becoming the predominant form of esophageal cancer. The worldwide incidence of EA 
in 2012 was approximately 52 000 cases and the corresponding rate for ESCC was 398 000 
cases
5
. In Sweden the age standardised incidence rates for have been reported to be 2.1 per 
100 000 population for men and 0.4 per 100 000 for women regarding EA. These values are 
comparable to many European countries with the exception of national hot spots such as the 
United Kingdom (7.2) and The Netherlands (7.1). Corresponding values for ESCC in Sweden 
are 1.5 and 0.7
5
. The average incidence increase for EA was calculated to be 4.9% annually 
in men and 3.9 % in women between 1970 and 2004
6
. Esophageal cancer occurs mainly in 
males with a risk of ESCC being 3-4 times higher and the risk of EA 7-10 times higher in 
men compared to women 
7
. Moreover these tumours develop predominantly in older persons 
(>65 years). 
1.1.3 Prognosis 
The long term survival for patients suffering from esophageal cancer continues to be poor. 
Early symptom may be vague and at the time of symptom driven medical consultations up to 
70 % of the patients are found to be incurable due to advanced or metastatic disease 
8
. Many 
patients are also considered inoperable because of concomitant disease. In Sweden 28 % of 
patients with esophageal cancer underwent curative resection 2006-2013
9
. Overall 5-year 
survival irrespective of treatment is 16.9 %, with only minor differences between genders and 
ethnic backgrounds
10
. Survival after treatment with curative intent have improved over the 
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past decades possibly because of better staging with exclusion of patients with metastatic 
disease, but also due to advances in surgical technique, postoperative care and the 
introduction of neoadjuvant therapy. Five-year survival after curative treatment is now 
reported to be as high as 44.4 %
11
 and survival rates tend to be even higher in clinical trials 
compared to real life population-based studies. In Sweden, five-year survival after esophageal 
resection with curative intent was 38 % during 2011-2014
9
. Most patients die from recurrent 
local or metastatic disease mainly in the liver, lungs or bone despite curative treatment. 
Tumour stage is an important factor for long term survival
9
.  
1.2 TREATMENT MODALITIES FOR ESOPHAGEAL CANCER 
1.2.1 Diagnosis and staging 
Confirmation of disease is done by endoscopy with biopsy for histopathological analysis and 
this also helps to define the tumour level; upper-, middle- or lower-esophagus, or GE 
junction. The determination of the tumour level at the GE-junction is important for deciding 
treatment modality and may be challenging if a hiatal hernia is present or because the actual 
GE-junction may be obscured by the tumour. Further staging is performed with computerized 
tomography, preferably with the addition of positron emission tomography to increase the 
sensitivity for detecting metastatic disease.  
1.2.2 Assessment for surgery and patient comorbidities  
Patients with esophageal cancer are often burden by comorbidities and due to the 
invasiveness of esophagectomy, preoperative risk assessment is of the highest significance. 
Several risk scoring systems have been proposed to facilitate selection of patients for surgery, 
but their usefulness has often been found to be limited due to overestimating mortality and 
failing to identify patients at risk for severe morbidity precisely enough
12, 13
. Few data exist 
regarding patients >80 years, and the effect of age per se has not convincingly been 
demonstrated
14, 15
. Historically, esophageal cancer patients have been treated as one group but 
with the increasing incidence of EA this needs to be diversified. Patients with EA are often 
over weight to obese. Accordingly, diabetes, hypertension and cardiovascular diseases are 
frequently seen as comorbidities. In addition to these risk profiles, patient with squamous cell 
carcinoma often present with a history of alcohol abuse. Hypertension and cardiovascular 
disease are also common in this group and in both groups smoking and chronic obstructive 
pulmonary disease are common. All of these comorbidities are known to have an adverse 
impact on the postoperative course and should be optimally treated before surgery. Patients 
with esophageal cancer may also suffer from malnutrition, which adds another risk factor for 
postoperative morbidity
16
. 
Evaluation of respiratory function by spirometry is a valuable tool and a forced vital capacity 
<80 % or a forced expiratory volume in one second <70 % have been linked to both 
pulmonary and non-pulmonary postoperative complications
17
. Medication to relieve 
obstructive complaints should be optimised and preoperative smoking cessation is 
imperative. Preoperative respiratory muscle training (as supervised by a physiotherapist) 
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might also be of value
18
. A cardiac exercise test or cardiopulmonary exercise test where 
maximum work capacity, anaerobic threshold and maximum oxygen uptake are measured, is 
one of the best evaluated tests in the preoperative testing of each individual patient to 
objectify general physical capacity and thereafter the postoperative risk. However further 
research is needed to increase the discriminatory ability of these tests
19-21
.  
1.2.3 Oncological treatment 
During the last decade studies have accumulated to show that neoadjuvant oncological 
treatment for esophageal cancer improves survival and neoadjuvant treatment is therefore 
regarded as standard of care in many countries today. Meta-analyses have shown that 
neoadjuvant chemotherapy (CT) as well as chemoradiotherapy (CRT) increase overall 
survival
22
 even though there is substantial heterogeneity within the studies regarding tumour 
types, radiation doses, chemotherapy regimens, methods of preoperative staging and 
treatment delivery, as well as sample sizes in the respective studies. Chemotherapy is most 
often administered as a combination of drugs given in two to three cycles. Typically 
platinum-based drugs are combined with 5-Fluorouracil. Recently a combination of 
carboplatin and paclitaxel showed good results with good treatment tolerance 
23
. However no 
real consensus exists regarding the optimal treatment plan. For adenocarcinoma perioperative 
chemotherapy is also an option and have shown improved survival rates compared to surgery 
alone
24
. Studies comparing neoadjuvant and perioperative chemotherapy are currently 
ongoing. 
In all modern protocols radiotherapy is given concurrently with chemotherapy. Different 
regimes have been used in published studies with doses ranging from 1.75-3.7 Gy/fraction 
and total dose ranging from 35-50.4 Gy
22
. Doses above 2 Gy/fraction are avoided nowadays. 
It is of particular importance to reduce radiation toxicity to adjacent organs, primarily the 
lungs. In a study by Lee et al it was reported that postoperative pulmonary complications 
increased significantly when more than 40% of the total lung received radiation doses higher 
than 10 Gy (V10>40 %) 
25
. Further studies by Wang indicated that the percentage of lung 
tissue spared from doses >5 Gy might be an even better indicator
26
. 
Whether neoadjuvant CT or CRT is the best approach to increase long term survival is 
debated. Only two randomised head to head comparative studies have explored this important 
question
27, 28
 but none of them was large enough to offer robust conclusions regarding e.g. 
long term survival. The NeoRes study, from which a cohort of patients was further studied in 
this thesis, was initiated to investigate the rate of complete histological response after 
neoadjuvant CT vs. CRT. Complete histological response has been proposed as a marker of 
increased long term survival
29, 30
. There are also concerns that neoadjuvant CRT may increase 
postoperative morbidity and mortality but the results are conflicting
23, 31-33
. Little is known 
about the underlying physiological mechanisms for this possible increase in morbidity and 
mortality from neoadjuvant CRT. Neoadjuvant CT has on the other hand never been shown 
to increase postoperative complications compared to surgery alone
22
.  
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nCT, neoadjuvant chemotherapy; nCRT, naoadjuvant chemoradiotherapy 
Figure 1. Kaplan–Meier plot of overall 3-year survival according to treatment group in the 
NeoRes study. Reproduced with permission from Annals of Oncology (Klevebro, Nilsson 2016). 
Recently, during the preparation of this thesis, the main results from the NeoRes study were 
published. Complete histological response, which was the primary outcome was achieved in 
28 % in the CRT group vs. 9 % in the CT group, p=0.002. CRT also yielded a higher R0 
resection rate (87 % vs. 74 %, p=0.04), and a lower frequency of lymph-node metastases (35 
% vs. 62%, p=0.001). However this did not translate into an increased 3-year survival rate 
(CRT 47 % vs. CT 49 %, p=0.77, Figure 1)
34
. There was also an increased mortality in the 
CRT group during the first year following randomisation from causes other than tumour 
recurrence (CRT: 11 out of 24 deaths, CT: 3 out of 20 deaths, p = 0.036). 
Patients with ESCC can also be treated with definitive CRT, which includes a higher 
radiation dose compared to neoadjuvant treatment. Studies comparing definitive CRT with 
curative intent for ESCC have shown results comparable to neoadjuvant treatment and 
surgery
35-38
, but these studies have been hampered by a substantial degree of protocol 
deviation. In patients who respond poorly to definitive CRT or have a local recurrence, rescue 
esophagectomy that carries a high risk of postoperative mortality can be performed in 
selected cases, provided that there is no metastatic disease
39
. Whether neoadjuvant therapy 
followed by resection or definitive CRT followed by rescue esophagectomy in selected cases 
is the best treatment for ESCC has yet to be determined in future studies.  
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1.2.4 Surgical technique 
Historically surgery has been the curative treatment for esophageal cancer. The first 
transthoracic esophagectomy was performed by Franz Torek in 1913
40
. Today several 
techniques are available depending on tumour localisation and the need for 
lymphadenectomy. For T1a disease (no invasion of submucosa) organ sparing endoscopic 
resection and if present, eradication of residual Barret’s esophagus mostly with 
radiofrequency ablation has >95 % local control rate
41
. The widely used two field open Ivor 
Lewis approach starts with a laparotomy to mobilise the stomach and resect the gastro-
omental, gastric and celiac trunk lymph nodes. The stomach is usually formed into a narrow 
gastric tube. Thereafter the patient is turned into the left lateral position for a right posterior 
thoracotomy which allows access for resection of the esophagus and mediastinal lymph 
nodes. The gastric conduit is then anastomosed to the remnant esophagus in the thorax to 
restore intestinal continuity. Ivor-Lewis esophagectomy is performed for lesions of the GE-
junction and lower or middle esophagus. For more proximal tumours, the McKewn 
procedure, which is performed in the reversed order and finished with a cervical incision for 
the anastomosis is applied. Trans-hiatal esophagectomy which excludes thoracotomy and 
therefore necessitates blind dissection of the upper thoracic oesophagus can be applied for 
distal tumours and an extended total gastrectomy including the distal esophagus can be 
performed for tumours in the GE-junction. These procedures have the advantage of being less 
invasive than a thoracoabdominal procedure, but do not allow for a complete mediastinal 
lymphadenectomy. In later years minimally invasive procedures involving laparoscopy and 
thoracoscopy either together or combined with open surgery have been developed and 
introduced to an increasing extent. So far results have mainly been obtained from non-
randomised studies. These have shown benefits in favour of the minimally invasive approach 
including decreased major morbidity, pulmonary complications, anastomotic leakage, 
mortality, length of hospital stay, operating time and blood loss 
42
. One multicentre 
randomised trial comparing total minimally invasive and open approach was in favour of the 
minimally invasive approach regarding postoperative complications and quality of life and a 
another study comparing laparoscopically-assisted with open esophagectomy showed similar 
results
43
. 
1.2.5 Anaesthetic technique 
Anaesthesia for esophageal resection is challenging. Although ventilation of both lungs is 
feasible during the thoracic part of the procedure, commonly the right lung is deflated during 
open thoracotomy to facilitate the surgical access and exposure. A thoracic epidural is the 
main form of pain control and has been shown to decrease pulmonary complications
44, 45
 and 
endorse early extubation as well as allowing early mobilization of the patient
46
. Early 
extubation is nowadays used routinely in clinical practice. Fluid administration is a major 
concern as excessive fluids both during and after surgery may be linked to increased 
morbidity
47
 although this was not confirmed in a recent meta-analysis
48
. The concept of goal-
directed therapy can be used to guide fluid administration. However, the application of goal-
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directed therapies varies and these can also be questioned regarding their effectiveness 
although a decreased morbidity has been claimed
49
. It also appears that the group to benefit 
most from such therapy is the high risk surgical group, i.e. as represented by those 
undergoing an esophageal resection
50
. Hypovolaemia also needs to be avoided as impaired 
tissue perfusion will decrease organ function and might negatively affect the healing 
processes of the anastomosis. On the other hand the use of vasopressors to increase mean 
arterial pressure (MAP) did not affect the anastomotic micro circulation when studied in an 
animal experimental model
51
. However, the answer to the most important question: How 
different fluid regimes and vasoactive therapies affect the microcirculation in the anastomosis 
remains elusive, as an adequate methodology to measure anastomotic circulation over time in 
vivo is currently lacking. Recently, enhanced recovery protocols including early mobilization 
of the patients have reported decreased length of stay as well as decreased cardio- respiratory 
morbidity compared to conventional postoperative care
52, 53
, albeit that robust scientific 
evidence behind the true relevance of the various components contained within these 
enhancement recovery programs is lacking. The type of anaesthetic used during surgery can 
affect the inflammatory response but results are conflicting and no clear advantage of any 
particular agent is currently known
54
.  
1.2.5.1 One Lung Ventilation 
One-lung ventilation (OLV) with deflation of the right lung has traditionally been used during 
the open, thoracic part of the operation to facilitate surgical access and exposure. OLV is 
associated with a number of potential drawbacks such as the risk of oxygen toxicity by free 
radical formation after re-oxygenation. This risk is generated by high FiO2 delivered to the 
ventilated lung and also from increased production of oxygen radicals at the re-ventilation of 
the occluded lung. Other risks related to OLV are barotrauma, atelectasis and possibly 
ischaemia-reperfusion injury
55
, which adds to the already high risk of postoperative 
pulmonary complications seen after esophagectomy. During OLV pulmonary shunting 
increases from 10 to 30% due to hypoxic vasoconstriction in the non-ventilated lung
56
. 
Surprisingly this does not increase net lung vascular resistance when pulmonary hypoxia is 
not global, but the underlying mechanisms are poorly understood
57, 58
. Protective strategies 
consist of reducing plateau pressures to below 25 cm H2O, low tidal volumes, pressure 
controlled ventilation, dependent lung positive end expiratory pressure (PEEP) and 
permissive hypercapnia
59
. These strategies have been shown to dampen some of the 
inflammatory responses caused by one-lung ventilation
60
.The concept of protective 
ventilation is mainly carried over from the ARDSNet trial in which an improved outcome in 
patients with acute respiratory distress syndrome (ARDS) was demonstrated
61
. OLV may 
even trigger the inflammatory response to surgery, possibly originating mainly from the 
ventilated lung. This reaction may then be maintained locally over the following days as 
revealed by increased cytokine concentrations in pleural drains fluid compared to plasma
62
. 
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1.3 COMPLICATIONS AFTER ESOPHAGECTOMY 
The overall postoperative complication rate after esophageal surgery is high with a morbidity 
in the range of 30-50%
23, 63
and an in hospital mortality in the range of 2.9-5.3 %
64
. 
Respiratory complications are the most common and include acute lung injury, ARDS, 
pneumonia and respiratory insufficiency. Combined thoracoabdominal incision, micro- or 
macro aspiration from the gastric conduit, fluid overload and comorbidities (smoking and 
alcohol abstinence) contribute to the risk for respiratory complications. Early mobilization 
and the ability to cough are important preventive as well as treatment strategies. Atrial 
fibrillation is the most common cardiovascular complication affecting 20-25 % of the 
patients
65, 66
. This may also be the first symptom of a surgical complication and it is therefore 
important always to search for background-triggering factors
65, 67
. Besides surgical 
complications, fluid overload, local inflammation, partial vagal denervation and inability to 
continue regular beta-blockers may trigger atrial fibrillation. Anastomotic leakage is the most 
important surgical factor behind the high mortality after esophagectomy
68
. Other 
complications specific for this surgical procedure include chylothorax from thoracic duct 
leakage and recurrent laryngeal nerve palsy. To prevent severe complications early detection 
is fundamentally important. This requires familiarity with these patients amongst all hospital 
staff involved as well as established pathways for diagnosing and treating emerging 
complications. As a result, during the last decade esophageal cancer surgery have been 
centralised into high volume centres, where the mortality after esophagectomy is substantially 
lower compared to low volume centres
68, 69
. 
1.4 INFLAMMATORY RESPONSE AND RELATED REACTIONS 
Inflammation, derived from the Latin word inflammatio (ignite, to set alight) is the process 
by which the body attempts to stop or remove harmful stimuli. Triggering factors are for 
example the presence of bacteria or bacterial endotoxins, tissue damage and cell death or 
ischaemia-reperfusion. A multitude of immune cells are attracted to the site of injury by 
endocrine and paracrine signalling from the damaged area as well as autocrine signalling 
among the cells from the innate immune system already present. Local blood flow and 
vascular permeability is increased to facilitate the recruitment of immune cells from the 
bloodstream to the site of injury. These cells then proceeds to eliminate pathogens and 
damaged cells through a plethora of mechanisms. During this process normal tissue function 
is impaired and further tissue damage can ultimately follow
70
.  
1.4.1 The immune system 
The immune system is typically divided into the innate and adaptive systems. The innate 
system is mature at birth and is always active to provide an initial reaction to a stimulus. It 
consists of macrophages and neutrophils that ingest microbes, natural killer cells that kill 
infected cells and dendritic cells that together with macrophages present antigens to the 
adaptive immune system. Complement factors that either help to attract more immune cells 
(chemotaxis) or attack cells by disrupting the cellular membrane via an enzymatic cascade 
also belong to the innate system
70
. 
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The adaptive or acquired immune system develops in response to an antigen. The response is 
slower than the innate response but the reaction to the antigen is stronger and once 
encountered the adaptive immune system will remember the antigen. The adaptive system is 
divided into humoral and cellular immunity. The humoral immunity consists of B-
lymphocytes which secrete antibodies and also have an antigen-presenting capability. T cells 
are the cellular part of the adaptive system. There are several forms of T cells; the most 
abundant are T-helper cells and cytotoxic T-cells. T-helper cells are activated following 
major histocompatibility complex II presentation of an antigen by an antigen presenting cell. 
They then multiply rapidly and enhance and regulate the immune response through cytokine 
release. Cytotoxic T-cells kills host cells infected by intracellular microbes, viruses as well as 
tumour cells by inducing apoptosis 
70
. Cytotoxic T-cells are activated by recognition of a 
foreign peptide presented by the host cell through major histocompatibility complex I which 
is present in all nucleated cells. All cells of the immune system produce cytokines and related 
factors that can regulate the function of other types of cells. CD45 or tyrosine phosphatase, 
receptor type C is a regulatory protein expressed on all leukocytes. It is routinely used to 
histologically identify leukocytes using immunohistochemistry. 
1.4.2 Cytokines 
Cytokines are proteins that have immune modulating effects by creating signalling pathways 
between different immune cells and also directed towards other cell types, which can both 
produce and react to cytokines. Cytokines are numerous and act in complex patterns to 
modulate the immune response as well as promote cell differentiation and growth. They are 
often divided into pro- and anti- inflammatory cytokines although many contribute to both 
effects to some extent. A large group of cytokines are called interleukins (IL) as they are 
produced by and act on leukocytes. Major pro-inflammatory cytokines are IL-1α and IL-1β, 
IL-2, IL-6, TNFα and IFN-y71. Major anti-inflammatory cytokines include IL-1ra, IL-4, and 
IL-10
72
. Chemokines (chemotactic cytokines) form a subclass of small cytokines with a 
molecular weight in the range of 20 kD produced primarily by endothelial cells and 
macrophages to facilitate leukocyte adhesion and migration through the vascular 
endothelium
73
.Cytokine release is increased after esophagectomy and high levels of IL-6, 
TNFα, IL-1b, IL-10 have been linked to postoperative morbidity74-78. Perioperative 
corticosteroids have been shown to diminish the IL-6 and IL-8 response to esophagectomy, 
paralleled by a decreased postoperative morbidity. These data, although promising needs to 
be confirmed in future studies
79
. External radiation has been shown to increase the levels of 
IL-1b and IL-6, as well as lung specific TGF-beta1 and IL-13 when studied in a mouse 
model
80
. 
1.4.3 The complement system 
The complement system is part of the innate immune system and consists of a family of 
proteins circulating in the general blood stream in the form of inactive zymogens. C3 is the 
most abundant of these and is hydrolysed to the active form C3b in plasma at a low rate. C3b 
is rapidly degraded if not bound to an activating pathogen. Once C3b is triggered it initiates 
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an enzyme cascade at the site of activation
70
. There are three different pathways to 
complement activation (Figure 2). In the classical pathway complement C1 binds to 
antibodies attached to an antigen and thereby promotes ingestion by phagocytes with 
complement receptors. This process is called opsonisation. In the alternative pathway C3b 
binds directly to the surface of a microbe or antigen thereby initiating the cascade. Finally in 
the lectin pathway, plasma mannose-binding lectin binds to an antigen. Plasma-mannose 
binding lectin is similar, in its structure, to a component C1 in the classical pathway and can 
activate C4. Once activated, all pathways lead to activation of C5 which is the initiating step 
in the formation of the terminal complement complex (sC5b-9 or TCC). sC5b-9 induces 
hydrolysis by forming a transmembrane pore in the cellular wall. sC5b-9 was formerly 
regarded as the most important effector mechanism for complement activation and remains so 
in special cases such as Neisseria meningitides infections. However, a modulatory effect of 
sC5b-9 on the humoral immune response such as opsonisation and chemo-attraction is today 
considered more important
81
. sC5b-9 has also been implicated to mediate increased 
hyperpermeability of the pulmonary endothelium in a rat model
82
, and C3a and C5a are also 
important pro-inflammatory signals inducing chemotaxis of humoral immune cells. The 
complement system is complex and has numerous effects on the immune system and many of 
these are still poorly understood. Although initially thought to be activated only upon 
infection the complement system is now recognized to react to any form of tissue trauma 
such as, for example, surgery and ischemia reperfusion
83
. Dysregulation of the complement 
system is also involved in many auto-immune diseases as well as organ transplantation and 
targeted treatments of complement factors are today used for a few rare diseases
84, 85
. 
 
Figure 2. Schematic view of the complement system illustrating the three activation 
pathways as well as the main effector mechanisms of opsonization, inflammation and lysis. 
Reproduced with permission from Nature Reviews Immunology (Zipfel, Skerka 2009).  
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1.4.4 Nitric oxide 
Nitric oxide (NO) is a free radical consisting of one nitrogen atom with a covalently bound 
oxygen atom with an unpaired electron. It is an odourless and colourless gas in its free form. 
In the late 1980s an unknown endothelial relaxant was discovered which was later on 
demonstrated to be NO
86
. Since then many different functions of NO have been discovered. 
In 1998 Furchgott, Ignarro and Murad were awarded the Nobel Prize “for their discoveries 
concerning NO as a signalling molecule in the cardiovascular system”. 
NO is a potent vasodilator by relaxing smooth muscle and is the active substance in 
nitroglycerine, long used to treat angina pectoris. However, NO also contains anti- as well as 
pro-inflammatory effects leading to impaired platelet adhesion, regulation of cytokine 
production in the endothelium and among the immune cells, and is involved in the 
inflammation seen after ischemia-reperfusion
87
. In vivo NO is synthesized from L-arginine 
by three isoforms of nitric oxide synthases (NOS), further named from the tissue in which 
they were found: neuronal NOS, endothelial NOS and inducible NOS (iNOS) which is 
induced in several cell types including macrophages and neutrophils in response to 
inflammation.   
NO has a short half-life of only milliseconds depending on the micro environmental 
conditions under which it is released. Local NO concentration, its ability to diffuseand the 
concentration of other bio reactants are major factors that regulate NO stability
88
. Its short 
half-life makes NO difficult to measure. Therefore the terminal end products of NO 
breakdown, nitrite and nitrate, are often used as indirect estimates of NO production. Nitrate 
is the major end product when a sufficient amount of O2 is present
88
. 
NO has been shown to reduce pulmonary vasoconstriction in healthy volunteers during 
hypoxemia
89
 and to reduce pulmonary arterial pressure rise during cardiac surgery
90
. OLV, 
on the other hand, does not increase pulmonary artery pressure
57, 58
 and NO administered 
during OLV, did not affect mean pulmonary artery pressure during OLV
91
.  
1.4.5 Endothelin 
Endothelins are small polypeptides, which exist in three isoforms (1-3), are produced by 
many cell types throughout the body and secreted in an auto or paracrine fashion
92
. 
Endothelin-1 is the main contributor to vascular tone. It is formed predominantly in 
endothelial cells and is a powerful vasoconstrictor considered to act as a natural counterpart 
to NO. There are two major receptors for endothelin called ETA and ETB. ETA is selective for 
endothelin 1 and 2 and thought to be the main pathway for the vasoconstrictive effect while 
ETB is non-selective and believed to mediate a broader range of effects such as endothelin-1 
clearance, endothelial cell survival, and induction of NO through regulation of endothelial 
NOS. There are several feed-back loops between NO and endothelin. Moreover NO inhibits 
the release of endothelin and endothelin elicits release of NO
93, 94
. ETA receptors are present 
both in the pulmonary vascular endothelium and in the airway smooth muscle cells mitigating 
both vascular as well as bronchial constriction
92
. Increased levels are present both in 
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symptomatic asthma and in pulmonary hypertension. Endothelin levels has been found to 
increase following ischemia reperfusion injury in animal studies and blockage of endothelin 
by receptor antagonists have been shown to attenuate lung injury following ischemia 
reperfusion
95, 96
. This indicates that endothelin also plays a role in ischemia reperfusion 
injury. 
1.4.6 Ischemia-reperfusion injury 
Ischemia-reperfusion injury is a complex pathophysiological event characterized by 
intracellular injury, dysregulation of circulation, inflammation and increased permeability of 
capillaries and arterioles
97, 98
. Ischaemia induces an anoxic cell injury with loss of electrolyte 
and imbalanced water homeostasis leading to necrosis (cell death) or apoptosis (programmed 
cell death without release of harmful substances). When reperfusion occurs, reactive oxygen 
species are formed augmenting oxidative stress and recruiting cytokine synthesizing 
neutrophils. The NO-Endothelin balance is shifted leading to a decrease of NO and increase 
in endothelin. The net effect of that is vasoconstriction and even arrested microcirculatory 
flow which will further increase tissue damage. Apart from vasodilation, NO appears to have 
both beneficial and harmful effects in this pathophysiological setting. During oxidative stress 
endothelial NOS may produce the highly reactive peroxynitrite which can induce cell death 
although it might also act as a free radical scavenger
99
. Beneficial effects include decreased 
neutrophil infiltration through down regulation of pro-inflammatory cytokines and up-
regulation of anti-inflammatory cytokines as well as inhibition of apoptosis
100
. 
Ischaemia reperfusion injury is important in clinical settings such as myocardial infarction, 
stroke, cardiopulmonary bypass and organ transplantation
101-103
. One-lung ventilation during 
esophagectomy has been suggested to induce an ischaemia-reperfusion injury when the 
collapsed lung is re-ventilated. In a porcine model the NO metabolite nitrite was decreased 
following OLV and there were signs of vascular congestion in the lung
104
.  
1.5 CENTRAL HEMODYNAMICS 
Tissue oxygen delivery is the end product of the circulatory system. With the exception of the 
small amount of free dissolved oxygen in the blood it is directly proportional to haemoglobin 
levels, haemoglobin saturation and cardiac output (CO). Cardiac output is controlled by heart 
rate (HR) and stroke volume (SV). Stroke volume is determined by preload, afterload and 
cardiac contractility. Preload is the grade of stretch in the sarcomeres of cardiac myocytes at 
the end of diastole. It is commonly assessed by end diastolic volume (EDV) and/or end 
diastolic pressure. Afterload is the pressure the heart must overcome in order to eject blood 
out of the heart i.e. the systemic (SVR) or pulmonary resistance. SVR is calculated as SVR= 
(MAP-CVP)/CO where MAP is mean arterial pressure and CVP is the central venous 
pressure measured at the right atrium. Contractility is the force generated in the sarcomeres of 
the myocytes by actin myosin cross-bridges during systole. Contractility is dependent on a 
number of factors including stretching of the myocytes. At low levels of stretch (preload) 
fewer actin-myosin cross-bridges are formed and less force is generated. 
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Figure 3. Illustration of the Frank-Starling 
relationship. Stroke volume will increase 
rapidly with increasing preload when preload is 
low. As the myocytes become overstretched 
further increase in preload will lead to a 
decreased stroke volume. 
 
  
With increasing preload more cross-bridges are formed and more force is generated. 
However, if preload increases too much, actin and myosin become too separate to form cross-
bridges and contractile force will decrease. This is called the Frank-Starling relationship 
(Figure 3) and means that given a static afterload and HR, SV will increase with increasing 
preload until the myocytes become overstretched, at which point SV will start to decrease.  
Measuring contractility is difficult and in vivo involves the direct and simultaneous 
measurement of pressure volume curves during sudden changes of preload
105, 106
. Today this 
can be accomplished by heart catheterization using a conductance catheter and intermittent 
vena cava occlusion but the method is still complex and invasive. Other indirect methods 
such as echocardiography and SV measurement exist. This is discussed further below. 
1.6 THE HEART CYCLE 
In the early part of systole, ventricular pressure rises and the pulmonary and aortic valves are 
closed. This is called isovolumetric contraction. Thereafter the aortic and pulmonary valves 
open and blood is ejected from the heart. Flow is initially fast as ventricular pressure exceeds 
aortic pressure and then slows down as the pressure gradient drops. Systole ends with closure 
of the aortic and pulmonary valves when vascular pressure exceeds the ventricular pressure. 
At that point the remaining blood volume in the left ventricle, referred to as the residual 
volume, is used to calculate the ejection fraction (EF) as EF= (EDV-residual volume)/EDV. 
Early diastole is called isovolumetric relaxation where there is a substantial drop of pressure 
inside the ventricle as the myocytes relax. When the ventricle pressure drops below the atrial 
pressure, the mitral and tricuspid valves open and the rapid filling phase begins. During the 
rapid filling phase blood is sucked passively into the ventricles, and this phase contributes the 
largest portion of the EDV. A small volume is added by blood returning through the atria 
from the periphery or lungs during the following phase named diastasis. Finally the atria 
contract thus adding the final portion of EDV. Contribution to EDV from atrial contraction 
increases with increasing heart rate as the time for diastasis is shortened. However if HR is so 
high that the rapid filling phase is impaired, EDV will decrease
107
. 
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1.7 HEART FAILURE 
Heart failure is defined as the physiological state in which CO is insufficient to meet the 
oxygen needs of the body. In systolic heart failure contractility is decreased. EDV is 
preserved or enlarged due to dilation but SV is decreased leading to a lower EF. In diastolic 
heart failure the rapid filling phase is impaired i.e. the relaxation of the heart. As a result, 
EDV is decreased leading to a smaller SV but with preserved contractility and EF. Both 
systolic and diastolic heart failure produce similar symptoms of fatigue and stress intolerance, 
although patients with diastolic failure are more sensitive to tachycardia. Left ventricular 
failure generally produces respiratory symptoms such as dyspnoea, orthopnoea caused by 
pulmonary congestion while right ventricular failure tends to produce peripheral oedema 
from congestion in systemic capillaries. 
1.8 NT-PROBNP 
N-Terminal Pro-B-Type Natriuretic peptide (NT-proBNP) is a peptide hormone with 
vasodilatory and natriuretic effects. It is released from cardiac myocytes in response to 
myocardial stretch from volume overloading as well as from underlying structural 
abnormalities in patients with heart failure
108
. It is used to diagnose and exclude heart failure 
and also gives prognostic information
109, 110
. During the last decade preoperative and 
postoperative levels of NT-proBNP have been shown to predict postoperative cardiac 
morbidity and also mortality
111-115
. Radiotherapy for oesophageal cancer has also been shown 
to increase NT-proBNP levels
116
, but the prognostic significance of this finding is unknown. 
1.9 ECHOCARDIOGRAPHY 
Based on the principle of reflected ultrasonic waves, echocardiography has become the most 
common way of assessing cardiac function. There is a multitude of parameters for evaluating 
different functions and anatomical structures in the heart. Guidelines on how to acquire 
images and interpret them have been published
117
. The most widely used parameter, which is 
also easiest for the non-specialist to interpret, is EF. However both the acquisition and the 
interpretation of images are user-dependent, which reduces reproducibility. Many 
echocardiographic parameters are also affected by preload and afterload making assessment 
of contractile function more difficult. In recent years strain has emerged as a parameter to 
assess contractile longitudinal or circumferential function of the heart
118-120
. Strain is the 
relative shortening of the distance between naturally occurring acoustic markers (speckles) 
within the endocardium. The length of shortening as well as the velocity of the speckles can 
be measured using a method called speckle tracking. Global strain (GS) is the average 
longitudinal strain of the different cardiac segments obtained from one projection (Figure 4). 
It is considered more sensitive than EF and less user dependent
121-123
, the latter largely due to 
its angle independence (having the transducer tilted slightly out of plane does not affect the 
values measured). Strain has been shown to have an excellent agreement in accuracy with 
methods considered to be have the highest accuracy; R
2
=0.9 vs sonomicrometry in dogs and 
R
2
=0.89 vs. magnetic resonance imaging
118, 124
. 
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Figure 4. Analysis of global longitudinal strain (GS) using EchoPac in a four chamber apical 
view. The strain of the six segments analyzed are shown in the bottom left window and the 
resulting GS in shown in the top left window. 
1.10 MINIMALLY INVASIVE HEMODYNAMIC MONITORING AND GOAL 
DIRECTED THERAPY 
The pulmonary artery catheter was the first method used to measure CO in routine practice. 
Today it has largely been replaced with less invasive methods even though it is still useful in 
some settings. A number of methods have been developed such as esophageal Doppler 
ultrasound, pulse contour analysis and pulse power analysis which is used in this thesis. The 
application of these techniques for preload optimization has been developed based on 
predicted changes of SV from dynamic flow parameters (stroke volume variation, pulse 
pressure variation, aortic blood flow velocity waveform)
125
. Optimization can also be 
performed by challenging the Frank-Starling curve of the heart either by rapidly infused fluid 
boluses or a passive leg rise test which increases venous return to the heart and therefore also 
preload
125, 126
. A patient is generally deemed a responder (on the ascending part of the 
pressure volume curve) if a SV increase >10 % is achieved by the intervention, i.e. an 
increase in preload.  
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2 AIMS 
The overall objective of this thesis was to explore a clinically challenging field closely 
connected to the surgical management of oesophageal cancer. In particular the thesis focused 
on physiological effects of single lung ventilation and neoadjuvant treatment and on the 
potential impact of these therapeutic concepts on the perioperative courses.  
Specifically we aimed to: 
 Compare the systemic inflammatory response and factors regulating pulmonary 
vascular tone, as elicited by the alleged ischaemia-reperfusion injury following one- 
or two-lung ventilation during the thoracic part of esophageal resection for cancer. 
 Compare acute effects on the preoperative cardiac function following neoadjuvant 
chemo- or chemoradiotherapy for cancer of the esophagus or gastro-esophageal 
junction. 
 Compare the perioperative hemodynamic profile, inflammatory response and 
respiratory function following neoadjuvant chemo- or chemoradiotherapy in patients 
undergoing thoracoabdominal esophageal resection for cancer. 
 
 
  17 
3 MATERIALS AND METHODS 
The general outlay and outcome measures in papers I-V are shown in Table 1. Both studies 
were performed at the Karolinska University hospital in Huddinge and included only patients 
with oesophageal or GE junction cancer. 
Table 1. Study design and outcome measures 
 Paper Design Intervention Setting Outcome N 
Study 
one 
Paper 
I & II 
Single centre 
prospective 
randomised 
controlled 
trial 
OLV or TLV Perioperative Cytokines, 
complement 
activation 
markers, 
NO/endothelin, 
clinical outcome 
30 
Study 
two 
Paper 
III 
Single centre 
prospective 
randomised 
cohort 
CT or CRT Post 
neoadjuvant 
treatment 
Systolic and 
diastolic 
echocardiographic 
parameters. NT-
proBNP 
40 
 Paper 
IV & 
V 
Single centre 
prospective 
randomised 
cohort 
CT or CRT Perioperative Hemodynamic 
parameters, 
echocardiographic 
parameters, NT-
proBNP, 
cytokines, 
complement 
activation 
markers, clinical 
outcome 
31 
3.1 ETHICAL CONSIDERATIONS 
In study one patients were randomised to either standard treatment with OLV or the 
experimental treatment of two lung ventilation (TLV) during the thoracic part of the 
operation. OLV is standard during esophagectomy, and although TLV has been used to a 
lesser extent there has been no indication that TLV has any specific safety issues. Blood 
sampling of pulmonary veins and arteries adds a small risk but any bleeding during surgery is 
easily detectable and treated during the operation. Lung biopsies also add a small risk for air 
leakage and pneumothorax, but this is not expected to have any clinical consequences since 
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all patients that underwent esophagectomy at this unit received bilateral thoracic drainages as 
standard care. No extra vascular accesses were used for blood sampling. However, the 
acquisition of lung biopsies represents an ethical dilemma. Given the high incidence of 
postoperative pulmonary complications following esophagectomy it is imperative to study the 
underlying factors in order to improve treatment. Given this, we considered the ethical 
dilemma as minor. In study two, patients with esophageal cancer were randomised to either 
CRT or CT, both of which are standard neoadjuvant treatments. Therefore this study does not 
have any particular ethical dilemmas from that perspective. The extended protocol at 
Karolinska Huddinge could be considered as cumbersome for the patient in terms of more 
hospital visits for different examinations but did not with the exception of lung biopsies entail 
any increased risks. 
The protocols for papers I-V were approved by the Stockholm regional ethics committee. All 
patients received written and oral information and were included after signing an informed 
consent form. For the lung biopsies in paper V, an additional consent was obtained. 
3.2 PATIENT CHARACTERISTICS 
A brief description of patient characteristics in each study is given in Table 2 below. A 
detailed description is provided in each paper. 
Table 2. Patient characteristics 
 Group 
n 
Age 
Median (range) 
BMI 
Median(range) 
Cardio-
vascular 
disease 
n (%) 
Smoking 
ongoing/ 
previous 
n (%) 
ASA 
class 
Median 
(range) 
Paper 
 I-II 
OLV 
n=16 
62.5 (33-74) 24.1 (17.3–32.8) - 10 2 (2–3) 
 TLV 
n=14 
66.5 (43–83) 22.0 (18.0–35.3) - 11 2 (2–3) 
Paper 
III 
CRT 
n=17 
66 (56–75) 26 (21–35) 10 (59) 4 (24) 2 (2–3) 
 CT 
n=23 
62 (46–71) 23 (18–33) 7 (30) 10 (43) 2 (2–3) 
Paper 
IV-V 
CRT 
n=14 
66 (56-75) 26 (21-34) 7 (50) 8 (47) 2 (2–3) 
 CT 
n=17 
60 (51-71) 23 (18-33) 6 (35) 2 (14) 2 (2–3) 
3.3 SURGERY 
Thoracoabdominal surgery (papers I, II, IV, V) was performed as described under 1.2.4. 
Reconstruction was performed using a narrow gastric tube in all but four cases (Study 1: 
OLV group 2, TLV group 1; Study 2: CT group 1) All patients received bilateral thoracic 
drains with active suction at the end of surgery as well as a jejunal catheter for postoperative 
nutrition. 
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3.4 ANAESTHESIA 
Anaesthesia (papers I, II, IV, V) was induced with Propofol 2-3 mg/kg and Fentanyl 2 µg/kg 
after placement of an epidural in the 6-8
th
 epidural space. A bolus dose of Fentanyl 50 µg was 
administered in the epidural after which an infusion with Bupivacain 2 µg/ml, Adrenaline 2 
µg/mL and Fentanyl 50 µg/ml was started at 10-15 ml/h. Anaesthesia was maintained using 
Sevoflurane at a concentration of 0.7-0.9 % minimal alveolar concentration together with the 
epidural and muscle relaxants. A Norepinephrine 40 µg/ml infusion was used as needed in 
order to maintain MAP at 60-70 mm Hg. Fluids were administered at a rate of 1 ml/kg/h of 
Glucose with electrolytes, Ringers acetate 2 ml/kg/h and 2 ml/kg/h of poly-hydroxyl-ethyl 
starch 130/0.4 (Voluven 60 mg/ml, Fresenius Kabi). Hypovolaemia was treated with poly-
hydroxyl-ethyl starch or blood products as deemed appropriate by the anaesthesiologist. All 
patients received a double lumen central venous catheter in the right jugular vein and an 
arterial catheter in the radial artery. All patients were extubated at the end of surgery and 
transferred to the postoperative recovery ward. 
3.4.1 Ventilation 
A double lumen endobronchial tube was used in all patients and placement was verified by 
bronchoscopy at insertion and after repositioning of the patient. During laparotomy patients 
were normoventilated using volume controlled ventilation with a PEEP of 4 cmH20 and peak 
pressures < 30 cmH2O. FiO2 adjusted to maintain PaO2>10 kPa. For papers I and II one-lung 
ventilation was commenced in the OLV group after thoracotomy by deflation of the right 
lung. Tidal volume was reduced to maintain the same top pressures as during TLV and 
respiratory rate increased as necessary to maintain a similar minute volume. FiO2 was 
increased to maintain PaO2 >10 kPa. A PEEP of 5 cm H20 was applied to the right lung using 
a Bains system with 100 % FiO2. In the TLV group top pressures and minute ventilation were 
maintained and respiratory rate and tidal volume was changed as needed.  
For papers IV and V the ventilation protocol was the same as for papers I and II during the 
abdominal part of the procedure. During the thoracic part, OLV was employed in all patients 
with the same goals regarding pressure levels and arterial PaO2. However PEEP was only 
applied to the right lung if PaO2 >10 kPa could not be maintained using FiO2 100 %. 
3.5 NEOADJUVANT TREATMENT 
In Study two (papers III-V) neoadjuvant therapy was employed as follows (Figure 5): 
Chemotherapy was given in three cycles of 21 days. Cisplatin 100 mg/m
2
 was given on day 1 
and 5-fluorouracil 750 mg/m
2
/24h was given on days 1–5. Cisplatin was switched to 
Carboplatin or Oxaliplatin in case of hearing impairment or renal dysfunction. Dose reduction 
was allowed in case of severe side effects. In the CRT group, concomitant radiotherapy was 
administered during cycles two and three in 2 Gy/day fractions 5 days per week for a total of 
40 Gy. Radiotherapy was planned using a computer tomography-based three-dimensional 
treatment planning system and dosing to adjacent organs was minimized using a multiple 
field technique 
127
. Surgery was performed 4-6 weeks after neoadjuvant treatment. 
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Figure 5. Neoadjuvant treatment. Cisplatin and 5-fluorouracil was given in three cycles. 
Radiotherapy 2 Gy/day was given concomitantly for a total of 40 Gy during cycles two and 
three. 
3.6 STUDY ONE; PAPERS I & II 
Study one was a prospective interventional single centre study including consecutive patients 
undergoing thoracoabdominal esophageal resection for esophageal or GE-junction cancer. 
None of the patients had received neoadjuvant therapy. Patients were randomised to receive 
ventilation of one or two lungs during the thoracic part of the procedure. Randomisation was 
performed during the operation, before thoracotomy by use of sealed, opaque envelopes. 
Analysers of samples were blinded to study group allocation. The same study population was 
used in papers I and II. 
3.6.1 Data acquisition paper I 
The first blood samples were collected from the central venous catheter after induction of 
anaesthesia. After thoracotomy, but before adjusting ventilator settings and instituting OLV, a 
second set of samples was drawn from the central venous catheter as well as the right inferior 
pulmonary vein. This was repeated before closure of the thorax (10 min after re-ventilation in 
the OLV group). Further central venous samples were collected in the mornings of POD 1-3 
and 10. Samples were centrifuged at 2500 g/4⁰C for 10 min before storing the supernatant at -
80⁰C in aliquots. Data regarding in hospital morbidity was obtained continuously from 
patients clinical records. 
3.6.2 Data acquisition paper II 
The first blood samples were collected from the central venous- and arterial catheters 
immediately after thoracotomy (before adjusting ventilator settings/instituting OLV). This 
was repeated before closure of the thorax (10 min after re-ventilation in the OLV group). 
Further central venous samples were collected in the mornings of POD 1-3 and 10. Samples 
were centrifuged at 2500 g; 4 ⁰C for 10 min before storing the supernatant at -80 ⁰C. Lung 
biopsies were taken from the lower lobe of the right lung before start of dissection of the 
thorax. Before closure of the thorax (10 min after re-ventilation OLV group) a second biopsy 
was taken from the same site. Biopsies were divided and fixed in a formaldehyde solution or 
immediately frozen in liquid nitrogen and stored at -80⁰C. Data regarding in hospital 
morbidity was obtained continuously from patients clinical records. 
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3.7 STUDY TWO; PAPERS III-V 
Study two, the NeoRes study, was a prospective, none blinded, interventional multicentre 
study in Sweden and Norway regarding histological response following neoadjuvant chemo- 
or chemoradiotherapy (CT and CRT) for esophageal or GE-junction cancer. Patients eligible 
for inclusion were adults <75 years deemed accessible for surgery with curative intent and 
with no major illness making neoadjuvant therapy unsuitable. Randomisation was performed 
by a computer based program at the Regional Oncological Centre in Stockholm and patients 
were stratified by histological type prior to randomization. A detailed description of the 
inclusion and randomisation process has been published by Klevebro et.al. 
127
. 
Patients scheduled to be operated on at Karolinska University Hospital were from January 
2009 also included in the prospective single centre observational cohort studies presented in 
this thesis. Added inclusion criteria were planned thoracoabdominal resection. Of the 41 
patients fulfilling these criteria 40 were analysed in paper III as intention to treat. In papers IV 
and V 31 of the 41 patients were analysed as per protocol (completion of resection). 
Analysers of blood samples and the performer of echocardiography were blinded to study 
group allocation. Study group allocation was not blinded during acquisition of hemodynamic 
measurements. 
3.7.1 Data acquisition paper III 
Before start of neoadjuvant therapy and 4-6 weeks after its completion an exercise test, 
echocardiography and measurements of NT-proBNP were performed in an outpatient setting 
(Figure 6). For details regarding the methodology of the respective test please see the 
respective sub heading below. 
 
*TTE, trans thoracic echocardiography 
.Figure 6. Time line for data acquisition in paper III in relation to neoadjuvant treatment.  
3.7.2 Data acquisition paper IV 
Echocardiography after neoadjuvant treatment was performed in an outpatient setting (the 
same examinations as in paper III) and repeated in the morning of the third postoperative day 
(POD). 
Baseline NT-proBNP was measured upon admittance for surgery. NT-proBNP and Troponin 
T were also measured after arrival to the postoperative ward POD 0 and in the mornings of 
POD 0-3. 
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In the morning of the day of surgery haemodynamic measurements after fluid optimisation 
were performed using LiDCOplus. This was done in the preoperative ward with the patient 
awake and at rest. During surgery haemodynamic data were collected at predefined time 
points (after 2 hr of abdominal surgery, 1 hr after start of OLV and after closure of the 
thorax). The monitor was not available to clinical staff to guide intraoperative treatment. On 
POD 3 haemodynamic measurements were repeated after fluid optimisation (Figure 7). In- 
hospital morbidity and mortality were accessed daily by the research team. 
 
*TTE, trans thoracic echocardiography. 
Figure 7. Time line for data acquisition in paper IV-V.  
3.7.3 Data acquisition paper V 
Baseline blood samples for routine chemistry were measured upon admittance for surgery 
and baseline blood samples for cytokine and complement activation markers were taken in 
the morning of the day of surgery in the preoperative ward. Further samples were collected at 
POD 0 after arrival at the postoperative ward and in the morning of POD 1-3 (Figure 7). 
Samples for routine chemistry were analysed by the Karolinska University Hospital 
accredited laboratory for clinical chemistry. Blood samples for cytokine and complement 
activation marker were centrifuged at 2500 g; 4 ⁰C for 10 min before storing the supernatant 
at -80 ⁰C. 
Arterial blood gases were drawn in the preoperative ward and at POD 0-3. Samples were 
analysed bedside using ABL 800 Flex (Radiometer Medical, Brønshøj, Denmark).  
Lung biopsies from the medial part of the right inferior lobe (within the radiation field in 
patients from the CRT group) were taken before closure of the thorax with a linear staple 
device, divided and immediately frozen in liquid nitrogen or stored in formaldehyde solution. 
In hospital morbidity and mortality were accessed daily by the research team. 
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3.8 ANALYTICAL METHODS 
The methods used in paper I-V are outlined in Table 3 and further described in the following 
sections 
Table 3. Analytical methods used 
 Paper I Paper II Paper III Paper IV Paper V 
ELISA X    X 
Radio immuno assay  X    
Chemiluminescence  X    
Histological assessment 
of lung biopsies  
 X   X 
Echocardiography   X X  
Exercise test   X   
Routine laboratory 
analyses  
X  X X X 
LiDCOplus
TM
    X  
Fluid optimisation*    X  
Blood gas analysis    X X 
Multiplex analyses     X 
mRNA analysis     X 
*Optimisation of stroke volume by fluid boluses and measured using LiDCOplus
TM
. 
3.8.1 Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) was used for analysis of cytokines and 
markers of complement activation in plasma (paper I, V). ELISA is a common method for 
biochemical analysis based on attaching the substance studied to a surface coated with a 
substance specific antibody. A second specific antibody is then applied over the surface, 
binding to the substance. This antibody is linked to an enzyme and, in the final step a 
substance containing the enzyme's substrate is added. The subsequent reaction produces a 
detectable signal, usually a colour reaction which can be quantified by a photo sensor. The 
method can be used to study a variety of substances and is considered highly quantitative and 
generally reproducible
128
. However only one cytokine per well can be analysed which 
increases costs and the sample amount used. Commercial kits are available for many analyses 
although results can vary according to antibody quality and kit manufacturer as well as 
operator skill. Analyses were performed by our research group and by the research group of 
Professor K. Nilsson-Ekdahl at Department of Immunology, Genetics and Pathology, 
Uppsala University. For details on specific kits and reagents used see papers I and V 
(page333 and page 9). 
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3.8.2 Radioimmunoassay 
Radioimmunoassay was used for plasma Endothelin analysis (paper II). Briefly, this method 
is based on the competition of radioactively labelled antigen and non-labelled (cold) antigen 
in the study sample in binding to an antigen-specific antibody. When the cold antigen is 
added, marked antigen is displaced from the antibody binding sites into the solution. By 
measuring radioactivity in the solution the concentration of antigen in the sample can be 
calculated. Analyses were performed by the research group of Professor J.O. Lundberg at 
Department of Physiology and Pharmacology, Karolinska Institutet. The exact methodology 
used has been described in detail by Lundberg et al.
129
.  
3.8.3 Chemiluminescence 
Chemiluminescence was used to analyse plasma nitrite (paper II). In brief, the method entails 
reductive cleavage of nitrate by iodine to form NO. NO then reacts with ozone to form N2O. 
A portion of the N2O formed arises in an electronically excited state and emits light upon 
decay which is measured by a photo sensor. Analyses were performed by the research group 
of Professor J.O. Lundberg at Department of Physiology and Pharmacology, Karolinska 
Institutet. The exact methodology used has been described in detail by Lundberg et al.
130
. 
3.8.4 Histological assessment of lung biopsies 
Lung biopsies were cut to 8-10 µm thickness and mounted onto slides. In paper II 
immunofluorescence was used to score levels of iNOS in lung biopsies at 60x magnification 
and hematoxylin-eosin staining was used for arbitrary scoring of vascular congestion. The 
immunofluorescence method utilizes a primary antibody against iNOS. A secondary antibody 
against the constant part of the first antibody and finally a tertiary antibody against the 
secondary antibody. The tertiary antibody also contains a fluorescent dye. Examination is 
then performed by fluorescence microscopy. Analyses were performed by Associate 
Professor L. Ny at Department of Oncology, Gothenburg University. For details on specific 
kits and reagents used see paper II (page 855). In paper V the numbers of CD45 positive cells 
in the interalveolar stroma were counted in three high power fields per biopsy at 40x 
magnification. Staining for CD45 was performed by the Karolinska University Hospital 
accredited laboratory for pathology using commercial immunohistochemistry kits (DAKO, 
Agilent Technologies, Inc.), counting was performed by Professor Å. Öst at the Department 
of Pathology, Karolinska Institutet. 
3.8.5 Echocardiography 
Transthoracic echocardiography was used in papers II & IV to assess global and regional 
systolic function as well as diastolic function of the left ventricle. As there is significant intra-
observer variability in acquiring and interpreting ultrasound images, all examinations except 
three in papers III and four in paper IV were performed by the same laboratory technician 
using the same Vivid 7 ultrasound scanner and a standard 2.5 mHz transducer (GE Vingmed, 
Horten, Norway). Furthermore, all post-processing analysis was performed by me using Echo 
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PAC (GE Vingmed, Horten, Norway). A standard cardiac examination was performed in all 
patients. One or more loops of three heartbeats were recorded for each online view and stored 
for post-processing. As echocardiography results are greatly dependent on image quality, this 
was optimised as much as possible during the examination by use of probe and patient 
positioning, probe frequency, focus depth, sector width and gain (strength of incoming 
signals i.e. image brightness).The best cardiac cycle from each view was used in post 
processing. Further quality optimization was also performed during post-processing. Both 
performer and interpreter of the examinations were blinded to study group allocation at the 
time. In each examination the following measurements were made (Figure 8): Global systolic 
function was evaluated by EF (using the Simpson biplane method) and global strain (GS). 
Regional systolic function was evaluated by mitral annular plane systolic excursion 
(MAPSE) of the septal septum (sept) and the basal anterolateral wall (lat) using tissue 
doppler. Diastolic function was evaluated by measuring peak blood flow velocities across the 
mitral valve during diastole, E- and A-wave. The E-wave (E) is generated during the early 
filling phase when the ventricle relaxes and the A-wave (A) from the late filling phase when 
the atria contract. Details on measurement acquisition are presented in paper III (page 3). 
 
E and A denotes blood flow velocities across the mitral valve. EF, Ejection fraction; EDV, end diastolic volume; 
ESV, end systolic volume; GS, global strain; MAPSE, mitral annular plane systolic excursion. 
Figure 8. Illustration of measurement points from a four chamber apical view during 
echocardiography. Reproduced with permission from Radiation Oncology (Lund, Kalman 2014). 
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3.8.6 Exercise test 
Standard exercise tests of maximum working capacity by use of a bicycle ergometer were 
performed before start of neoadjuvant treatment and repeated 4-6 weeks after completion of 
treatment (paper III). The purpose was not primarily to detect cardiac ischemia but rather to 
provide the maximum working capacity as an objective measurement of the patients’ general 
fitness. All tests were performed at a hospital physiology department and supervised by a 
dedicated member of staff. 
3.8.7 Routine laboratory analyses 
C-reactive protein, leukocyte count, NT-proBNP and Troponin-T (papers I, III-V) were all 
analysed by the Karolinska University accredited laboratory for clinical chemistry (ISO 
15189) by electrochemiluminescence immunoassay. 
3.8.8 Haemodynamic measurements 
LiDCOplus
TM
 (LiDCO Ltd, London, UK) (paper IV) is a device for continuous minimally 
invasive measurement of SV, utilising changes in the energy content of arterial resistance 
vessels (pulse power analysis). It is based on two steps. The first is calibration of the volume 
of the arterial resistance vessels (arterial waveform stroke volume curve) by use of lithium 
dilution. A small dose of lithium chloride is injected into a (central) vein and blood is drawn 
through a lithium sensitive sensor by use of a roller pump connected to an arterial line in the 
radial artery. The ensuing concentration curve is then integrated to achieve a direct 
measurement of CO much like thermodilution when using a pulmonary-artery catheter. This 
is then used to correct the algorithm used for continuous monitoring and in the second step 
data from the arterial line are copied from the regular monitor, analysed and displayed on the 
LiDCO monitor. During continuous monitoring, beat to beat measurement of SV can be 
performed and events added to track if changes in SV and CO occur following an 
intervention. As with all methods for measuring SV, it is sensitive to atrial fibrillation as that 
will cause a variation of SV. Other sources of measurement error include dampening and 
reflected arterial waves. However, using pulse power analysis, the impact of these sources 
can be minimised using autocorrelation. The method is well validated and has shown good 
correlation with the pulmonary-artery catheter over a wide range of stroke volumes
131-136
. 
This method was chosen for its ability to be used in an awake patent, during surgery and then 
again on the third postoperative day with an awake and mobilized patient. During 
measurement great care was taken in order to standardize the measurement situation. Pain 
was assessed using a visual analogue scale with a range of 0-10 and managed until the score 
was below 4. The patient was resting in bed with the researcher and monitor behind a screen 
during all measurements. All volume measurements were indexed for body surface area 
before statistical analysis. 
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Hb, haemoglobin; PaO2, arterial partial pressure of oxygen; VAS, visual analogue scale; MAP, mean arterial 
pressure; SV, stroke volume; PLR, passive leg rise. 
Figure 9. Flow chart of fluid optimization. A stroke volume increase > 10 % following a 
3 ml/kg bolus of poly-hydroxy-ethyl-starch 130/0.4 indicated a responder. Boluses were 
repeated as long as SV increased >10 % per bolus. If SV increase was 8-9 % a passive leg 
rise was performed. After optimization hemodynamic values were recorded.  
3.8.9 Fluid optimisation 
Fluid optimisation using LiDCOplus was performed in the preoperative ward before surgery 
and repeated on postoperative day 3. Boluses doses of poly-hydroxy-ethyl-starch 130/0.4 
(Voluven 60 mg/ml, Fresenius Kabi) 3 ml/kg (2.5 ml/kg if BMI> 30) were infused at a rate of 
1200 ml/hr. A SV increase of > 10 % following a bolus was considered to indicate a 
responder. Boluses were repeated as long as SV increased >10 % per bolus. When SV 
increase was borderline (8-9 %) a passive leg rise (PLR) was performed
137
 (Figure 9). The 
haemoglobin value used in calculations of DO2I was adjusted down by 5 % per bolus to 
account for hemodilution.  
3.8.10 Blood gas analysis 
Arterial blood gases were drawn during adequate pain relief (visual analogue scale below 4) 
and with the patient breathing room air for a minimum of 10 min for measurement of 
PaO2/FiO2-ratios (paper V). If saturation was less than 85 % on ambient air a Hudson RCI® 
oxygen mask (Teleflex, Morrisville, USA) with an oxygen flow of 5 L min
-1
 was used for a 
FiO2 of 0.4 according to the manufacturer. For intubated patients FiO2 was recorded from the 
ventilator. For the haemodynamic measurements preoperatively and on POD 3 FiO2 was 
adjusted to achieve PaO2 > 10 kPA (paper IV). Samples were analysed bedside using ABL 
800 Flex (Radiometer Medical, Brønshøj, Denmark). 
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3.8.11 Multiplex analysis 
Cytokines in plasma (paper V) were analysed using a flow-cytometry based multiplex assay 
(Luminex, Biorad systems, California, USA). This is a form of immune assay allowing 
simultaneous and rapid quantification of multiple cytokines from the same sample utilising a 
smaller sample volume than traditional ELISA. In brief, antibodies against the target cytokine 
are attached to different coloured beads. Then fluorescence or streptavidin labelled detection 
antibodies bind to the specific cytokine-capture antibody complex on the bead set. The 
resulting changes in light absorbance can be measured using flow cytometry. Compared to 
ELISA this method is cheaper, more time efficient and requires less volumes of sample
128
. 
Analyses were performed by the research group of Professor Mollnes at Centre of Molecular 
Inflammation Research, Norwegian University of Science and Technology. For details on 
specific kits and reagents used see paper V (page 8). 
3.8.12 mRNA analyses 
In paper V mRNA from lung biopsies acquired during operation were analysed using 
commercial kits. Total RNA was extracted and reverse transcribed to cDNA after 
concentration and quality measurements. Assessment of mRNA expression was performed 
with 18S rRNA as a reference gene and relative levels were calculated using a comparative 
Ct-method (i.e., 2
∆Ct-target gene
/2
∆Ct-reference gene
). Analysis was performed by the research group 
of Professor M. Rydén at the Department of Medicine, Karolinska Institutet. The exact 
methodology used has been described in detail by Gao et al
138
. 
3.9  STATISTICS 
Table 4 below presents an outline of the statistical methods used for papers I-V in this thesis 
Table 4. Statistical methods used 
 Paper I Paper II Paper III Paper IV Paper V 
ANOVA X     
Mann-Whitney U-test X X X X X 
Fischer´s exact test X X X X X 
Bonferroni post-hoc test X  X   
ANOVA on ranks  X    
Linear mixed models   X X X 
Holm-Šidàk correction    X  
3.9.1  Paper I 
Analyses of repeated measurements were performed on relative changes from baseline with 
analysis of variance (ANOVA) and time as the repeating variable. Data are presented as 
mean ± standard error of the mean (SEM) of relative changes from baseline, except for CRP, 
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which is presented as median and range. The Bonferroni correction was used to account for 
multiple testing. 
3.9.2 Paper II 
Analyses of repeated measurements were performed with ANOVA on ranks with time as the 
repeating variable. Data are presented as median and interquartile range. 
3.9.3 Paper III 
A linear mixed model was used to test repeated measurements for changes within the groups 
over time (within group changes) as well as changes between the groups over time 
(interaction effect). Several mixed models were used for each variable and to each model one 
of a set of covariables was added to test for any impact on the results. Covariables were 
chosen from patient characteristic and comorbidities with possible effects on the variables 
tested, for example age, hypertension, and ischaemic heart disease. Non parametric data were 
normalised using log transformation. The covariance structure was unstructed (assuming no 
relationship between the repeated measurements). The Bonferroni correction was used to 
account for multiple testing.  
3.9.4 Paper IV 
A linear mixed model was used to test for within group change and the interaction effect over 
time. Several mixed models were used for each variable and to each model one of a set of 
covariables was added as described above to test for any impact on the results. Non 
parametric data were normalized using log transformation. The covariance structure was 
autoregressive meaning less correlation was assumed between repeated measurements the 
further apart they were in time. In post hoc testing the Holm-Šidàk correction was used. The 
Holm-Šidàk correction was chosen as it is slightly less restrictive than the Bonferroni 
correction. Thus it might be seen as more appropriate in hypothesis generating post hoc 
testing. 
3.9.5 Paper V 
A linear mixed model was used to test for within group change and the interaction effect over 
time. Several mixed models were used for each variable and to each model one of a set of 
covariables was added as described above to test for any impact on the results. Non 
parametric data was normalised using log transformation. The covariance structure was 
autoregressive. 
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4 RESULTS AND DISCUSSION 
The present thesis is based on two parts, mutually interconnected, addressing various aspects 
of the perioperative courses connected with esophagectomy for cancer. In total this work 
comprises five individual papers designated as I through V. Details regarding methods and 
results can be found in the respective papers. The key results are discussed here in the context 
of pathophysiology and implications for the management of esophageal or GE-junction 
cancer 
4.1 STUDY ONE (PAPERS I-II) 
This was a randomised trial comparing OLV (n=16) and TLV (n=14) during esophagectomy. 
The two groups were well balanced regarding patient characteristics. Operative 
characteristics in terms of bleeding, operative time and time of modified ventilation were also 
similar in the two groups, which suggest that there were no major technical difficulty 
associated with TLV during the thoracic part of esophagectomy. No differences in 
postoperative morbidity were observed. 
The main finding in paper I was that the terminal complement complex (sC5b-9) increased 
more in the OLV group on POD 3 and 10 compared to the TLV group (Figure 10) while the 
increase of C3a was similar in both groups throughout the study period. Thrombin 
Antithrombin III complex (TAT) peaked in plasma at the time of reventilation while IL-6 
peaked on POD 2 and CRP on POD 3. Both groups expressed a similar pattern and there 
were no differences between the groups regarding these compounds. 
 
 
 
 
 
 
 
 
 
(○) OLV, one lung ventilation 
group 
(●) TLV, two lung ventilation 
group. 
 
Figure 10. Plasma levels of C5b-9 (TCC) expressed as % increase from baseline. Analyzed 
with ANOVA and presented as mean ±SEM. *p<0.05. Reproduced with permission from Journal of 
Surgical research (Tsai, Ekdahl 2009). 
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In paper II plasma levels of nitrite and endothelin did not display any differences between the 
groups. In fact nitrite levels measured from the superior vena cava (central venous catheter) 
and radial artery did not display any significant within group change (directly before vs 
directly after the thoracic part of the procedure) in either group. Nor did endothelin levels 
change significantly during the study period in either central vein or radial artery (Figure 11). 
The levels of iNOS and vascular congestion, assessed in the 14 cases where lung biopsies 
were available, did not indicate any difference between the groups. 
 
(○) OLV= one lung ventilation group, (●) TLV=two lung ventilation group 
Figure 11. Endothelin (ET-1) in central vein and radial artery before and after altered 
ventilation as well as on POD 1-3 and 10. There were no significant changes in either group 
during the study period. Analyzed with ANOVA on ranks and presented as median and 
interquartile range. Reproduced with permission from Diseases of the Esophagus (Lund, Tsai 2012). 
4.1.1.1 Aspects on inflammation and complement activation markers   
The postoperatively increased levels of sC5b-9 in the OLV group vs. the TLV groups is an 
indirect sign of an increased systemic inflammation after OLV since sC5b-9 is coupled to a 
parallel increase of C5a, which has pro inflammatory properties such as chemotactic effects 
on immune cells. C5a was not measured directly. sC5b-9 has also been linked to 
hyperpermeability of the pulmonary endothelial barrier
82
. C3a as well as sC5b-9 started to 
increase on POD 2 in both groups but there were no differences between the groups regarding 
C3a. POD 2 is the approximate time point where respiratory complications typically start to 
manifest after esophagectomy
139
, and the increase of sC5b-9 in the OLV group might indicate  
a relationship to respiratory postoperative complications. There was also an increase of TAT 
that may be linked to the increase of sC5b-9. TAT is a marker of thrombin generation, which 
is connected to the complement system through its ability to activate C5
140
. However this 
pathway of activation of C5 did probably not occur herein as there were no differences in 
TAT levels between the groups and because the increase of sC5b-9 was delayed compared to 
TAT. Kvarnström et al have also reported a similar temporal pattern of sC5b-9, C3a and IL-6 
in a study on major abdominal surgery during 24 h after surgery
141
.  
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C5b-9 and C3a, IL-6 and TAT were also analysed in samples from the right inferior 
pulmonary vein after re-ventilation and found to be increased to a similar extent in both 
treatment groups compared to before start of thoracotomy. However, except for TAT, the 
levels were low compared to those measured in the general circulation indicating that the 
lungs might not be the primary source of these factors at this time point. The levels of TAT 
and complement factors in the pulmonary vein later on during the postoperative course are 
unknown as postoperative sampling from the pulmonary veins was not possible to perform. 
Complement activation has been shown to correlate with ARDS and inhibition of 
complement reduces lung injury both in the experimental
142
and in the clinical setting
143, 
144
.The delayed increase of sC5b-9 that was shown could be speculated to represent a “second 
hit” in the lungs following OLV. Furthermore any possible effects on local inflammation 
were probably not mediated by sC5b-9 induced lysis, but rather from its potential ability to 
increase pulmonary endothelial permeability or from a pro inflammatory effect induced by 
C5a, although this was not measured. 
Our data seem to indicate a temporal correlation between sC5b-9 and the emerging of 
postoperative complications, although the mechanism of action for sC5b-9 and its origin is 
unknown. This small study could not show any correlation between the levels of sC5b-9 and 
postoperative complication, although it should be noted that the four patients with the highest 
levels of sC5b-9 all developed complications requiring an extended time in the intensive care 
unit. It is also interesting to note that we found no differences regarding plasma levels of CRP 
or IL-6, which have been associated with postoperative complications in several studies
74, 78, 
145
 suggesting that OLV does not induce more systemic inflammation compared to TLV.   
Based on these observations it can be concluded that OLV induces a delayed increase of 
sC5b-9 that in our study seems to coincide with the development of postoperative respiratory 
complications. However the pathway of activation of sC5b-9, its precise effect and clinical 
relevance is unknown. 
4.1.1.2 Aspects on factors regulating pulmonary vascular tone  
Acute lung injury from OLV may occur both in the ventilated and non-ventilated lung but for 
different reasons. The dependent lung is mainly damaged from hyperperfusion and over 
distension while the non-ventilated lung is damaged from surgical trauma, hypoperfusion and 
possibly also ischaemia-reperfusion injury. However the end result after any of these events 
will always be acute lung injury with an increase of inflammatory cells, cytokines and 
vascular oedema in the lung
146
. Ischaemia reperfusion injury in the lung triggers an 
inflammatory reaction including a large number of mediators including NO and endothelin
87
. 
Ischaemia reperfusion occurs in transplantation, cardiopulmonary bypass and arguably from 
all forms of OLV
146
, but this has not been studied in detail during esophagectomy. From 
studies in rodents it has been shown that both NO and endothelin are increased by OLV
95, 147
. 
However the balance might be shifted by a down regulation of NO as reported in a porcine 
study
104
. On the contrary, arterial endothelin levels were reported to be increased only in 
patients undergoing pneumonectomy compared to lobectomy in a human study
148
. NO has 
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been used as treatment for hypoxaemia and increased pulmonary vascular pressure during 
OLV in several studies and although results are not completely consistent, it appears that NO 
treatment is only beneficial in the presence of pulmonary hypertension
149
. 
In paper II we were unable to detect any effect from OLV compared to TLV on major factors 
influencing pulmonary vascular tone (NO, iNOS and endothelin) and there were no signs of 
increased vascular congestion in the lungs in the analysis of lung biopsies. By use of these 
respective methods we could thus not find any signs of ischaemia-reperfusion injury after 
OLV in contrary to what is often proposed. Although not statistically significant, the largest 
change recorded regarding endothelin-1 was the increase of arterial levels immediately at the 
end of surgery in the TLV group. This could be due to manipulation and compression of the 
right deflated lung which might lead to endothelin release. 
Based on these observations we suggest that OLV does not seem to affect pulmonary 
vascular tone or induce an ischemia reperfusion injury and thus maintains its place as 
standard care during open thoracoabdominal esophagectomy. 
4.1.2 Limitations to be considered for papers I-II 
There are several important limitations that needs to be considered. The primary endpoint 
(frequency of re-intubation) was not analysed due to early closure of the study after the start 
of a new multicentre study (the NeoRes study, paper III-IV), which resulted in a limited study 
population (n=30). Results are further limited by missing data from lung biopsies (paper II). 
Furthermore, we did not analyse C5a in paper I, which would have been interesting to do 
since it represents earlier steps in the complement cascade, possibly offering the option to 
elucidate which pathway that was increased. Also, the addition of a PEEP of 5 cmH20 with a 
FiO2 of 100 %, to the non-ventilated lung during OLV, may have attenuated the hypoxic 
vascular response sufficiently to prevent an ischemia-reperfusion injury becoming manifest 
upon reventilation (paper II).  
The statistical analyses in paper I were performed with ANOVA and in paper II with 
ANOVA on ranks for repetitive measurements. Although acceptable in parametric testing 
and possibly in non-parametric testing after normalisation of data by rank scale or log 
transformation, these approaches may be suboptimal. Corresponding studies are always 
exposed to the risk of type II error (false positive) even although the Bonferroni correction 
was applied to adjust for multiple testing. 
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4.2 STUDY TWO (PAPERS III-IV) 
All patient were consecutively included from the NeoRes trial but the demographics were 
slightly different in paper III compared to papers IV and V (Table 2), as the patients in paper 
III were included in the analysis at an intention to treat base while patients in papers IV and V 
were analysed as per protocol (i.e. those who completed an esophagectomy). This difference 
in inclusion for analysis allowed us to analyse all patients that underwent echocardiographic 
assessment in paper III. Data regarding radiation doses to the heart and lungs and rate of 
incomplete neoadjuvant treatment according to protocol are given in Table 5. 
Table 5. Heart and lung radiation and rate of incomplete neoadjuvant treatment 
 Paper III Paper IV-V 
V10 heart,% median (range) 74.9 (50.0-92.2) 72.0 (50.0-92.2) 
V30 heart, % median (range) 29.0 (0-80.1) 40.0 (0-80.0) 
V20 lung, % median (range)  8.7 (1.0-14.6) 
Avrlung, Gy median (range)  6.9 (3.4-10.4) 
     
Incomplete chemotherapy 
n (%) 
CT 
3 (13) 
CRT 
2 (12) 
CT 
4 (24) 
CRT 
2 (14) 
Incomplete radiotherapy 
n (%) 
  
1 (6) 
  
1 (7) 
CT, chemotherapy; CRT, chemotradiotherapy; Avrlung, average dose to total lung volume. 
Summary of radiation doses to the heart and lungs and incomplete neoadjuvannt treatment in 
papers III-V. V10, V20 and V30 denote the % of organ volume having received more than 
10, 20 and 30 Gy respectively.  
The main findings in paper III (CRT, n=17; CT, n=23) were a decrease in regional systolic 
function (MAPSE sept) and diastolic function (E and E/A ratio) and a concomitant increase 
of NT-proBNP associated with CRT (within group effect, Table 6). However the 
corresponding interaction effects did not reach significance (p=0.09, 0.09, 0.39 and 0.07 
respectively).No changes were seen following CT. Maximum work capacity also decreased 
in both groups following neoadjuvant treatment but the interaction effect did not reach 
significance (p=0.10). 
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Table 6 Results of Echocardiography, NT-proBNP and exercise tests in paper III 
 Chemotherapy  Chemoradiotherapy   
Variable Pre neoadjuvant Post neoadjuvant Pa Pre neoadjuvant Post neoadjuvant pa pb 
EF (%) 59 (56–62) 57 (53–60) >0.99 60 (57–64) 59 (55–63) >0.99 0.80 
GS (%) –17.6 (–16, –19) –15.7 (–14, –17) 0.26 –17.3 (–16, –19) –16.1 (–14, –18) >0.99 0.59 
MAPSE sept (cm/s) 12.5 (11.5–13.5) 12.1 (11.2–13.1) >0.99 12.6 (11.4–13.8) 11.1 (10.1–12.2) 0.02 0.09 
MAPSE lat (cm/s) 11.5 (10.4–12.6) 11.2 (10.2–12.3) >0.99 11.2 (10.0–12.4) 11.0 (9.8–12.1) >0.99 0.96 
E (cm/s) 72.0 (62.6–81.4) 68.1 (62.2–74.1) >0.99 78.8 (68.4–89.3) 64.1 (57.2–70.9) 0.01 0.09 
A (cm/s) 67.8 (58.2–77.5) 74.6 (63.9–85.3) 0.37 82.0 (71.1–92.7) 83.7 (71.6–95.9) 0.98 0.41 
E/A 1.08 (0.93–1.25) 0.95 (0.81–1.10) 0.43 0.97 (0.82–1.14) 0.77 (0.65–0.92) 0.03 0.39 
NT–ProBNP (ηg/l) 93 (58–149) 108 (70–167) >0.99 65 (32–130) 154 (92–260) 0.05 0.07 
Exercise test (W) 150 (135–165) 133 (115–151) 0.03 151 (133–151) 118 (96–140) 0.001 0.10 
Data are presented as mean (95% confidence interval). 
a
Mixed models test of within-group changes; 
b
Mixed models test of interaction effect; EF, ejection 
fraction; GS, global strain; MAPSE, mitral annular plane systolic excursion; NT-proBNP, N-terminal pro-brain natriuretic peptide.Reproduced with permission 
from Radiation Oncology (Lund, Kalman 2014). 
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(○) CRT=chemoradiotherapy, (●) CT=chemotherapy. SVI, Stroke volume index; CI, cardiac index; HR, heart 
rate; Hb, Haemoglobin level; DO2I, Oxygen delivery index; SVR, Systemic vascular resistance.  
Figure 12 A-F. Haemodynamic profiles during the study period. There were no significant 
interaction effects (p
1
). B; Preoperative CI was lower in the CRT group (p
2
). Linear mixed 
models, presented as mean and 95 % confidence interval.  
In paper IV (CRT, n=14; CT, n=17) we observed a decreased CI at baseline (as measured in 
the pre-operative ward before surgery) in the CRT group compared to the CT group. This did 
not translate into a significant interaction effect for lower CI in the CRT group during the 
study period (p=0.06). Haemodynamic values changed in both groups during the study period 
but there were no significant interaction effects between the groups (Figure 12). On POD 3, 
both groups displayed an almost identical hyperdynamic state compared to baseline. 
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(○) CRT, chemoradiotherapy 
(●) CT, chemotherapy. 
Figure 13. NT-proBNP levels increased similarly in both groups during the study period. 
Linear mixed models. p
1
 interaction effect, p
2
 preoperative differences, presented as mean 
and 95 % confidence interval.group. 
The biochemical marker NT-proBNP increased similarly throughout the study period in both 
groups (Figure 13) while there were no differences in the levels of Troponin T in either 
group. In a post hoc statistical analysis of NT-proBNP levels on POD 3 we found higher 
levels in the patients that required time in the intensive care unit (p=0.03) but not in those that 
developed cardiovascular complications (p=0.06). Operative characteristics such as operating 
time, bleeding, transfusion and the volume of intravenous fluids administered during the 
study period were similar between the groups. There were no differences in cardiovascular 
complications between the groups. A downside of the per protocol analysis was that we 
detected a difference in patient characteristic in that the CRT group were older (66 vs. 60 
years, p=0.03) and had a higher body mass index (26 vs. 23, p=0.04).  
In paper V (CRT, n=14; CT, n=17) we detected that mRNA levels of IL-1β in lung biopsies 
from the medial part of the right inferior lobe were significantly higher in the CRT group 
compared to patients receiving CT alone 2.0 vs. 4.4 AU (p=0.007, Table 7). mRNA levels of 
other cytokines (IL-6, IL-8, IL-10, MCP-1) analysed were generally higher in the CRT group 
but these differences never reached statistical significance. Plasma levels of the same 
cytokines with the exception of IL-1β peaked immediately after surgery and there were no 
interaction effects between the groups. Plasma levels of IL-1β did not change at all (within 
group effect) during the study period and there were no interaction effects. The plasma levels 
of markers of complement activation all displayed within group changes of a similar pattern 
during the study period with no interaction effect. The number of leukocytes in the 
interalveolar stroma did not differ between the groups (p=0.53). PaO2/FiO2-ratios declined 
similarly in both groups and showed no tendency to improve at POD 3. Pulmonary 
complications were frequent in both groups (CRT 93 %, CT 65 %) but the difference in 
incidence between the groups did not reach statistical difference (p=0.09, Table 8). 
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Table 7. mRNA levels in lung biopsies 
 Chemo- 
therapy 
(n=15) 
Chemoradio- 
therapy 
(n=11) 
p 
IL-1β 2.00 (1.37-2.73) 4.41 (2.65-6.43) 0.007 
IL-6 6.52 (4.16-8.85) 8.94 (3.27-20.53) 0.16 
IL-8 9.53 (2.28-14.41) 17.45 (2.36-29.24) 0.39 
IL-10 3.71 (1.19-4.76) 4.24 (2.66-6.84) 0.28 
MCP-1 7.10 (2.35-11.16) 9.65 (5.01-21.19) 0.16 
The level of IL-1β mRNA in lung biopsises was significantly higher in the CRT group. 
Mann-Whitney U-test, presented as median and interquartile range of arbitrary units.  
 
Table 8. Postoperative complications in study two (paper IV-V) 
Complication n(%) Chemo-
therapy 
(n=17) 
Chemoradio-
therapy 
(n=14) 
P 
In hospital mortality 0 (0) 1 (7) 0.45 
Surgical complicationa 9 (53) 5 (36) 0.47 
MACEb 5 (29) 5 (36) 0.72 
Atrial fibrillationb 4 (24) 4 (29) 1.0 
Myocardial infarctionb 1 (6) 0 (0) 1.0 
Pulmonary complicationsb 11 (65) 13 (93) 0.09 
Pulmonary infectionb 3 (18) 4 (29) 0.67 
Respiratory failureb 11 (65) 11 (79) 0.46 
Sepsisc 3 (18) 3 (21) 1.0 
Respiratory failure was the most common complication. There were no significant 
differences in postoperative morbidity or mortality between the CT and CRT groups. 
Fischer´s exact test.
 a
Defined as any complication directly linked to the surgical procedure i.e. 
anastomotic leakage, chylothorax or similar. 
b
Defined according to ESA-ESICM guidelines 
(Jammer et al 2014). 
c 
Defined according to 2001 SCCM/ESICM/ACCP/ATS/SIS 
International Sepsis Definitions Conference. MACE: major adverse cardiovascular event. 
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4.2.1.1 Aspects on cardiac function following neoadjuvant treatment 
CRT has been suggested to increase postoperative morbidity and possibly also mortality, but 
the results from randomised studies of CRT are inconsistent
27, 28, 32, 33
. As radiotherapy for 
esophageal cancer will inevitably also affect adjacent thoracic organs, such as the heart and 
lung, impaired cardiac function might well be an important pathophysiological factor behind 
the alleged increase in morbidity and mortality. It is well known that delivery of external 
radiation to the thoracic cavity causes long term negative cardiac effects such as coronary 
artery disease, valvular disease, heart failure and pericardial disease
150
. However, many of the 
studies are old and used techniques for radiation therapy that are considered to be outdated 
today. On the other hand, with increasingly longer survival rates for many cancers such as 
breast cancer, these potential adverse effects have emerged as an expanding problem. Since 
these effects represent very late complications occurring 5-10 years or more after treatment, 
they may well be severely underreported
151
. There are few data concerning long term cardiac 
effects from radiotherapy for esophageal cancer, as long term survival historically has been 
very poor. In a study by Morota et al severe cardiotoxic events were found in patients 
receiving definitive CRT for esophageal cancer during a median follow up time of 26 
months
152
. 
There is some knowledge about acute radiation damage to the heart that originates mainly 
from old studies on the treatment of lymphoma
153
. During the last decade additional studies 
employing modern diagnostic techniques have indicated that acute cardiac impairment may 
follow thoracic radiotherapy for cancer. Mostly these studies have concerned radiotherapy for 
breast cancer
154-156
. Some studies have been performed in esophageal cancer patients 
although most of those studies are retrospective and limited by small sample sizes
157-159
. 
In a prospective study by Hatakenaka et al
157
 the level of cardiac impairment was even larger 
than presently observed and also included a global impairment of systolic function. The most 
likely explanation to these conflicting results could be that the radiotherapy treatment 
administered in that study (mainly palliative) contained larger doses and that other 
chemotherapeutic agents were administered. Otherwise our results concur with the those 
reported by Hatakenaka, in that the greatest systolic impairment of wall motion was found in 
the mid anteroseptal, mid inferoseptal and mid inferior segments, which is in accordance with 
our findings of decreased mitral annular plane systolic excursion of the septum (MAPSE 
sept). We also observed  that CRT decreased the blood flow velocities over the mitral valve 
during the fast, passive filling phase of the left ventricle (E), coupled with an unchanged 
blood flow during atrial contraction (A) and accordingly a decreased E/A. These data suggest 
an impaired diastolic function as a consequence of impaired relaxation of the left ventricle. 
This impairment of diastolic function could well occur as a result of acute inflammation 
affecting the myocardium and/or pericardium with oedema and decreased compliance caused 
by radiotherapy. It should be emphasized that we have no confirmatory observation on this as 
our study was not designed to investigate underlying mechanisms. 
Diastolic dysfunction is normally divided into five separate categories based on severity: 
Normal, impaired relaxation, pseudo normal, restrictive with reversibility and restrictive 
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without reversibility. A number of echocardiographic characteristics are used to differentiate 
between the groups. We abstained from applying such a classification since this would have 
severely diluted the power of our data, given the small sample size. Moreover the primary 
outcome variable in this paper was to evaluate systolic function by GS why only a limited 
number of variables for evaluating diastolic function were measured. We did not find a dose 
–response relationship between V30 and the echocardiographic or NT-proBNP changes. This 
could again be related to the small sample size or to the fact that V30 reflects the radiation 
dose to the whole heart volume rather than different segments. Due to the small sample size a 
segmental analysis was not performed. 
The increase of NT-proBNP, which we found in the CRT group, was small and not indicative 
of heart failure. However, NT-proBNP has also been launched as a predictor for the risk of 
perioperative cardiac complications, with cut off-levels between 201-791 ng/l
112, 113
. Pre and 
perioperative levels of NT-proBNP may accordingly act as predictors of postoperative atrial 
fibrillation even if cut-off levels have to be better defined
115
. It cannot be ruled out that the 
increase observed in the CRT group might be related to increased inflammation elicited by 
radiotherapy rather than cardiac impairment
160
. It should also be noted that we found no 
indication of cardiac impairment by echocardiography or NT-proBNP in the chemotherapy 
group. 
Both groups displayed a decrease in maximum work capacity assessed by exercise testing 
before and after neoadjuvant treatment and there was a trend towards a greater change in the 
CRT group (p=0.10). A decrease in exercise capacity following neoadjuvant treatment has 
previously been documented and has been suggested to be a predictor of postoperative 
morbidity
20, 161
. However when exercise tests from the entire NeoRes study population were 
analysed, the decrease in work capacity was completely abolished when adjusting results for 
haemoglobin levels
162
. This suggests that the decrease in work capacity might be mainly due 
to bone marrow depression from neoadjuvant treatment rather than from an effect on cardio 
respiratory function. 
Our data thus indicate that by adding external radiation therapy to neoadjuvant CT, a small 
acute impairment of regional systolic and diastolic function occurs and there is a slight 
increase in NT-proBNP levels. The clinical implications of this remain unclear both regarding 
long term effects, but also regarding the perioperative period which was further investigated 
in paper IV. 
4.2.1.2 Aspects on perioperative haemodynamics following neoadjuvant therapy 
Preoperative haemodynamic variables were generally lower in the CRT group although these 
differences never reached statistical significance except for CI. This resulted from a slight 
decrease of mean SVI coupled with a somewhat lower mean heart rate in the CRT group. 
This is in accordance with our findings in paper III which indicated a regional systolic as well 
as a slight diastolic impairment associated with CRT. These differences in preoperative 
testing are unlikely to be the cause of hypovolaemia, as measurements were performed in 
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both groups after fluid optimisation. With the exception of low haemoglobin levels, the 
preoperatively assessed mean haemodynamic values were all within normal limits in both 
groups. 
During surgery both groups behaved similarly with a decrease in all haemodynamic 
parameters. The lowest values were generally attained during the thoracic part of the 
operation. This pattern, as well as the absolute vales recorded, corresponded well to what has 
been reported previously during esophagectomy
163
. On POD 3, both groups displayed an 
almost identical hyperdynamic circulation with increased SVI, CI, DO2I and HR compared to 
baseline, which was coupled with a decreased SVR. This indicates that when exposed to the 
per- and postoperative stress, both groups were able to increase their cardiac performance to 
the same extent irrespective of which type of neoadjuvant therapy had been given. We found 
no significant interaction effect between the groups during the study period. 
NT-proBNP levels increased over time for the duration of the study period, reaching levels 
that might be predictive of an increased risk for postoperative cardiac events and mortality, as 
suggested by Rodseth et al
164
. This could potentially arise from the postoperative 
inflammatory response and fluid administration given to maintain intravascular volume. No 
correlation was found, however, between CRP (as a marker of inflammation) and NT-
proBNP (data not shown). Regarding fluid administration the largest fluid volume was 
administered during the day of surgery (about 8000 ml in each group) and the mean volume 
of fluids (enteral and parenteral) remained around 4000 ml/day in both groups. This 
corresponded to a mean weight gain of about 2.5 kg from baseline to POD 1 and a further 
weight gain of about 0.6 kg up until POD 3 (data not shown) which is commonly seen 
following major surgery. 
We did not analyse echocardiographic data as images acquired on POD 3 were of very low 
quality due to the mediastinal dissection and presence of drains and wound dressings. This is 
indicative of the difficulty in performing functional tests postoperatively in this group of 
patients, as previously reported by us concerning postoperative spirometry (paper I). 
The results from paper IV seem to confirm a slight but clinically questionable impairment of 
cardiovascular function as detectable in the resting state after CRT. More importantly these 
data suggest that a deficient adaptation of the cardiovascular system, when challenged by 
surgery, was not prevailing. Thus CRT as administered in this study does not appear to add 
an increased cardiovascular risk compared to CT in the perioperative setting. 
4.2.1.3 Aspects on perioperative inflammation following neoadjuvant treatment 
The enhanced local levels of IL-1 β mRNA in the lung parenchyma harbours an obvious 
potential to play a pathophysiological role in lung injury. Two recent studies, which 
investigated the respective effect of protective ventilation and continuous positive airway 
pressure (CPAP) during esophagectomy, found that both protective ventilation and CPAP 
was followed by lower levels of IL-1β in bronchial lavage fluid compared to the control 
groups
165, 166
. In addition, a relationship between systemic inflammatory responses and 
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postoperative complications after esophagectomy has been documented in several studies
74, 77, 
167
. It needs to be pointed out that the pulmonary IL.-1β gene expression can be up regulated 
following radiation without a concomitant increase in the circulation unless a second stimulus 
such as an infection or a trauma like surgery is added
168
. Besides having pro inflammatory 
properties, including induction of other cytokines and attraction of inflammatory cells, IL-1β 
has also been associated with increased wall thickness of the major airways, vascular 
congestion and fibrosis in rodent models
169, 170
. One of the key cytokines triggered by IL-1β is 
IL-6
168
 which is considered to be of importance for the postoperative inflammatory 
responses
171
. IL-6 production was found to increase in pulmonary epithelial cell cultures after 
esophagectomy in a study by Abe et al
76
. On the other hand, we were unable to detect 
significant differences in IL-6 between our study groups, both in plasma and in mRNA from 
lung biopsies. Again, clinical research addressing similar subtle pathophysiological 
mechanisms always face the issues of ample sample sizes and the correct timing of sample 
collection. 
Data from the complete NeoRes trial showed that although the final number of postoperative 
complications was not increased by CRT, the severity of the respective complications was 
greater
127
. The trial also found that the mortality rate from serious adverse events and 
postoperative complications was higher in the CRT group during the first year following 
randomisation
34
. However the underlying cause of the increased one year mortality is 
unknown. In the present cohort derived from the entire group of patients enrolled, we were 
able to study the respiratory complications in more details, including measurements of arterial 
blood gases, respiratory rates and detailed definition of respiratory complications. We report a 
pulmonary complication rate of 93 % in CRT vs. 65 % in CT group (p=0.09). Our data thus 
suggest that there might be a relationship between the enhanced expression of IL-1β mRNA 
expression in lung tissue and postoperative occurrence of pulmonary complications. These 
observations, taken together, describe a consistent pattern that suggests an enhanced risk for 
severe respiratory complications after esophagectomy when adding the current type of 
radiotherapy to chemotherapy. In a non-randomised cohort study that compared neoadjuvant 
CRT with surgery only
172
, a significant impairment of respiratory parameters both before and 
after surgery was shown in the CRT group. Postoperative heart rates and the duration of the 
systemic inflammatory response syndrome were also increased. We were unable to 
demonstrate corresponding clear differences between the CRT and CT groups. 
4.2.2 Limitations to be considered for papers III-V 
It is important to consider the impact of the small sample size (40 patients in paper III and 31 
patients in paper IV-V) on results. As the design of these studies included a cohort of patients 
enrolled in a larger study, no formal power calculations were found relevant for the endpoints 
addressed in papers III-V.  
Results are also limited by missing data. In paper III we were able to perform 
echocardiography examinations in only 67 % of patients, while in paper IV we were able to 
perform postoperative haemodynamic measurements in only 77 % of the patients. 
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These figures illustrate the complexity and many hurdles that affect the completion of 
complex perioperative physiological studies associated with demanding surgical procedures.  
In papers IV and V we observed an imbalance in age and body mass index between the two 
treatment groups. We handled this by adjusting the statistical model used for a set of co-
variables. This decreased the tendency for changes in CI as previously detected in paper IV, 
but otherwise no significant effects of these potential confounders were found. 
Possible limitations arising from our methodology were several. In paper III we used 
echocardiography which is known to be user dependent. Consequently, we used the same 
laboratory technician for performing the examinations and all post processing was performed 
by me without knowledge of treatment group allocation. Also, most echocardiographic 
parameters are influenced by preload (volume status). This could have affected our results as 
patients might be differently affected by catabolic/hypovolaemic issues depending on group 
allocation to neoadjuvant treatment. 
In paper IV LiDCOplus was used for haemodynamic measurements. While this is a validated 
method approved for clinical use it has limitations such as limited accuracy, especially during 
arrhythmias and in cases of aortic insufficiency. To increase accuracy we used three instead 
of the recommended two standard calibration points
132
. In the presence of arrhythmias, the 
average values acquired during 30 sec were used. Haemodynamic measurements are also 
sensitive to the level of physical activity, pain or emotional stress. This makes it important to 
standardise patient activity and overall situation during measurements especially following 
surgery. In order to mitigate this, great care was taken to control pain before measurement 
and to have the patient resting awake in bed. To avoid any influence from clinical staff or the 
researcher, no other activities took place during measurements and the researcher and monitor 
were hidden behind a screen. Values acquired during movement or coughing of the patient 
were disregarded. We also employed fluid optimisation during haemodynamic 
measurements. Although fluid optimisation is widely employed, often stroke volume 
variation or pulse pressure variation are used to assess the fluid responsiveness. This was not 
applicable in an awake, spontaneously breathing patient and so a modified protocol derived 
from Pearse et al 
126
 was used. This protocol was based on absolute changes of SV following 
a fluid bolus to guide further fluid administration rather than predicting the response from 
stroke volume or pulse pressure variation. This introduced the possibility of giving 
unnecessary fluid and possibly even worsening a situation with heart failure (as fluids given 
could even decrease SV). However no patient displayed a decrease in SV following any bolus 
during the study. 
In paper V, Multiplex analysis was used for measuring plasma levels of cytokines. Although 
the method has several advantages compared to traditional ELISA, some limitations have to 
be recognized. In Multiplex analysis it is critical that cross reactivity between any of the 
involved antibodies is avoided and that the antibodies are sufficiently specific. This is the 
case more so than for ELISA, as many cytokines are analysed in the same sample. The 
plasma preparation can also affect the levels of detectable cytokines as many of these are 
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bound to plasma proteins which may be affected by the preparation process. Moreover the 
underlying disease and concurrent state of inflammation have the potential to affect the levels 
of circulating proteins 
128
. Thus the use of plasma in paper V for Multiplex analysis instead of 
serum can hypothetically have affected the levels of cytokines detectable. 
  47 
5 CONCLUSIONS 
 
 One-lung ventilation induces a delayed increase in C5b-9 compared to two-lung 
ventilation during the thoracic part of esophagectomy. 
 One-lung ventilation during the thoracic part of esophagectomy seems not to affect 
factors regulating pulmonary vascular tone when compared to two-lung ventilation 
during esophagectomy. 
 Neoadjuvant chemoradiotherapy has an acute negative effect on both systolic and 
diastolic function of the heart but these effects do not prevail when the cardiovascular 
system is challenged by the stress of surgery. 
 The addition of radiotherapy to neoadjuvant chemotherapy increases the local 
inflammation in the right lung contained within the radiation field. 
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6 FUTURE PERSPECTIVES 
With the development of minimally invasive techniques for esophagectomy the use of OLV 
has declined but surgical treatment will remain the mainstay for curative treatment of 
esophageal cancer for the foreseeable future. However, as CRT with curative intent is starting 
to emerge as a possible treatment option in ESCC, surgery might not be the future primary 
treatment in this group even though data is currently lacking regarding how to best select 
patients. CRT with curative intent will invariably contain larger radiation doses than are 
currently given for neoadjuvant treatment and as such damage to surrounding organs will also 
increase. In any definitive CRT treatment rescue esophagectomy will have to be an option in 
cases with treatment failure. As a consequence the problem of radiation induced tissue 
damage may be even more important in the future management of patients with ESCC, 
particularly in those submitted to the very high risk procedure of rescue esophagectomy. 
Research avenues that have to be explored are those focusing on the mechanisms behind lung 
and cardiac injuries with the objective to better target radiotherapy and minimise the tissue 
damage, as well as targeting the negative effects in the perioperative setting. 
Furthermore, it is an open question as to how long a time should elapse between the cessation 
of neoadjuvant treatment and the resection of the esophagus. Accordingly, longitudinal 
studies on the natural course of changes in organ function, as presently observed, have to be 
performed in order to define the optimal time point for surgical intervention. The on-going 
NeoRes2 study investigates the effects of a longer time interval between neoadjuvant 
treatment and surgery and also includes serial NT-proBNP measurements. 
The introduction of minimally invasive esophagectomy techniques and enhanced recovery 
programmes for the postoperative rehabilitation of the patients, have and will have an 
important influence on the perioperative outcome. Still, the challenges of performing surgery 
consecutively in the two major body compartments persists and the pathophysiological 
mechanisms involved have to be better understood. Also the impact of age needs to be further 
explored. The age profile of future patients will change and more octogenarians will in the 
future be offered surgery for esophageal cancer. Therefore the specific impact of age on many 
of those parameters which have currently been explored in regard to neoadjuvant treatment 
has to be studied in more detail in order to adapt to the future demands of clinical medicine. 
With the predominance of adenocarcinoma in the current and most probably future 
population with malignancy of esophageus, it is most likely that a variety of aspects on the 
further development of neoadjuvant CT have to be taken into account. Novel drugs, and 
combinations of these, will be developed and tested in clinical situations. Many of those 
(together with those currently in use) will exert adverse effects on central organ functions 
such as the heart and respiratory tree. Given all of these preconditions, the respiratory 
complication rates will most probably remain significant and cannot be ignored. As a 
consequence of these changes, additional and complementary observational studies, based on 
the current methodology have to be designed and hypotheses need to be explored.  
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